A dead cat bounce is when a falling stock sees a short-term recovery, but is ultimately likely to head lower. It comes from the idea that “even a dead cat will bounce if it falls from a great height.” The stock market does not move in a straight line, and there are many ups and downs whichever way a stock moves. Thus, investors would be best served understanding which stocks are more akin to dead cats than recovery bids, particularly in this market.Many stocks with horrible fundamentals could plunge much fu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-31822 ACCELERATE DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1072256 (Stat ...

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - Chief Executive Officer, President & Director David Patience - Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Dustin Scaringe - William Blair Operator Good day, and welcome to the Accelerate Diagnostics Incorporated. First Quarter 2024 Results Conference Call. All pa ...

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.70 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this maker of systems that diagnose drug-resistant infections would post a loss of $0.62 per share when it actually produced a loss of $0.89, delivering a surprise of -43 ...

Financial Performance - Net sales for Q1 2024 were $2.9 million, a slight increase from $2.8 million in Q1 2023, with consumable product revenues rising by 7% year-over-year[4] - Net sales for Q1 2024 were $2,921,000, an increase of 3.9% compared to $2,812,000 in Q1 2023[20] - Gross profit decreased to $723,000 in Q1 2024 from $1,011,000 in Q1 2023, representing a decline of 28.5%[20] - The net loss for the quarter was $17.0 million, resulting in a net loss per share of $0.88[5] - Net loss for Q1 2024 was $16,965,000, slightly higher than the net loss of $16,795,000 in Q1 2023[20] - Basic and diluted net loss per share improved to $0.88 in Q1 2024 from $1.71 in Q1 2023[20] Cost Management - Gross margin for the quarter was approximately 25%, down from 36% in the same quarter last year, attributed to a lower mix of capital instrument product sales[4] - SG&A costs decreased to $5.7 million from $10.1 million in the prior year, primarily due to lower employee-related expenses[4] - Total costs and expenses significantly reduced to $10,879,000 in Q1 2024 from $17,073,000 in Q1 2023, a decrease of 36.4%[20] - Research and development expenses decreased to $5,173,000 in Q1 2024 from $6,968,000 in Q1 2023, a decline of 25.7%[20] Cash Flow and Liquidity - Cash used in Q1 2024 was approximately $9.0 million, net of financing, including about $1 million in pre-paid annual expenses[5] - Cash and cash equivalents increased to $14,606,000 as of March 31, 2024, up from $12,138,000 at the end of 2023[22] - Net cash used in operating activities decreased to $8,452,000 in Q1 2024 from $13,367,000 in Q1 2023, a reduction of 36.5%[22] Strategic Developments - The company installed its first pre-clinical trial site for the Accelerate Wave system, targeting a clinical trial start by the end of Q2 2024[2] - Contract extensions with strategic customers secured approximately 70% of the U.S. Pheno® customer base for longer-term contracts ahead of the Wave commercial launch[3] - The company added 12 new contracted Pheno instruments in the U.S., totaling 348 clinically live revenue-generating instruments by the end of the quarter[3] - The company continues to develop its Gram Positive PBC menu alongside the ongoing clinical trial work for the Accelerate Wave system[2] Liabilities and Accounts Payable - Total liabilities rose to $56,502,000 as of March 31, 2024, compared to $51,254,000 at the end of 2023, an increase of 10.3%[20] - The company reported a significant increase in accounts payable, which rose to $5,108,000 in Q1 2024 from $4,796,000 in Q4 2023[20]

The market expects Accelerate Diagnostics (AXDX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand ...

TUCSON, Ariz., May 2, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to review 2024 first quarter results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 2853328. International participants may dial +1.412.902.6506. Please dial in 10- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-31822 ACCELERATE DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1072256 (State or other jurisdiction of (I.R.S. Employer Identif ...

TUCSON, Ariz., March 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m. Eastern Time to review 2023 fourth quarter and full year results. To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days. To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 7172610. International participants may dial +1.412.902.6506. ...

TUCSON, Ariz., Jan. 19, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and for certain investors in lieu thereof, pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock. The public offeri ...